Seth Goldbarg, MD
Clinical Cardiac Electrophysiology · Flushing, NYNPI 1245279272
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Volta Medical Inc at 28.7% of the total. Reporting peaked in 2022 at $16,400 and has fallen 69.6% since, to $4,980 in 2025.
Across 262 payments — averaging $229.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Volta Medical Inc$17K
- Biotronik Inc.$15K
- Substrate HD$14K
- Biosense Webster, Inc.$4K
- Boston Scientific$3K
- Abbott$2K
- plus $5K from 12 others
Across 170 payments — averaging $1120.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Volta Medical Inc$112K
- Biotronik Inc.$42K
- Boehringer Ingelheim$22K
- Boston Scientific$15K
Across 5 payments — averaging $2626.63 each. An ownership or investment interest held by the physician or an immediate family member.
- Substrate HD$13K
What the payments were for
- Consulting fees$27,60646%
- Speaking & faculty fees$3,5276%
- Travel & lodging$12,05220%
- Food & beverage$16,84328%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Volta Medical Inc | 25 | $17,243 |
| Biotronik Inc. | 80 | $14,658 |
| Substrate HD | 3 | $13,875 |
| Biosense Webster, Inc. | 34 | $4,067 |
| Boston Scientific | 52 | $3,255 |
| Abbott | 18 | $1,886 |
| Atricure, Inc. | 7 | $1,866 |
| Medtronic(2 entities) | 17 | $898 |
| EBR Systems, Inc. | 4 | $680 |
| Sanofi-aventis U.S. LLC | 1 | $650 |
| Stereotaxis Inc | 1 | $326 |
| Johnson & Johnson | 9 | $227 |
| Janssen Scientific Affairs, LLC | 1 | $138 |
| Impulse Dynamics (USA) Inc. | 1 | $121 |
| Pfizer | 4 | $94 |
| Boehringer Ingelheim | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $21 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VX1$19,296
- Acticor 7 VR-T DX$3,173
- Carto 3 System$1,956
- ATRICLIP LAA EXCLUSION SYSTEM$1,663
- Edora$1,555
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$1,507
- BioMonitor$1,316
- AVEIR$1,054
- Carto 3$1,007
- WATCHMAN Access System$785
- Solia$755
- Rivacor$755
- Acticor$755
- MULTAQ$650
- Agilis NxT EP Introducer$450
- Rivacor 7 DR-T$434
- Selectra$410
- AMVIA EDGE$336
- Niobe$326
- Rhythmia Mapping System$295
How this compares
$60,058 in reported general payments places this provider in the 75th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 174 | $166,951 |
| XareltoRivaroxaban | 56 | $57,105 |
| EntrestoSacubitril/Valsartan | 27 | $26,456 |
| Amiodarone Hcl | 64 | $2,405 |
| Metoprolol Succinate | 109 | $1,836 |
| Propranolol Hcl ErPropranolol Hcl | 20 | $628 |
| Losartan Potassium | 20 | $300 |
| Atorvastatin Calcium | 32 | $287 |
| Metoprolol Tartrate | 30 | $211 |
| Amlodipine Besylate | 19 | $138 |
| Furosemide | 33 | $123 |
| SotalolSotalol Hcl | 12 | $96 |
| Carvedilol | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $94 | $166,951174 claims |
| Johnson & JohnsonXarelto | $227 | $57,10556 claims |
| NovartisEntresto | $16 | $26,45627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in Flushing
- George JuangFlushing$198K
- Vivek ReddyNew York$14.9M
- Jacob KoruthNew York$3.7M
- Srinivas DukkipatiNew York$2.7M
- Amir AhmadiNew York$789K
- Larry ChinitzNew York$448K
- Felix YangBrooklyn$407K
- James IpNew York$347K
- Stavros MountantonakisManhasset$321K
- Jorge RomeroSyracuse$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.